Cytotoxic capacity of hepatitis C virus (HCV)-specific lymphocytes after in vitro immunization with HCV-derived lipopeptides

Cytometry Part A

Volumn 65, Issue 1, 2005, Pages 59-68

  Langhans, Bettina ^a   Schweitzer, Susann ^a   Braunschweiger, Ingrid ^a   Schulz, Monika ^a   Sauerbruch, Tilman ^a   Spengler, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cytotoxic T lymphocyte; Flow cytometric cytotoxicity assay; Hepatitis C virus; Lipopeptides

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; HLA A2 ANTIGEN; LIPOPEPTIDE; PERFORIN; TETRAMER; VIRUS PROTEIN;

ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOBLAST; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADULT; ALLELES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HEPACIVIRUS; HUMANS; IMMUNIZATION; INTERFERON TYPE II; LIPOPROTEINS; MALE; MEMBRANE GLYCOPROTEINS; PHENOTYPE; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL CORE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 18044365595     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.20136     Document Type: Article

References (39)

1. Rehermann B, Chisari FV. Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 2000;242:299-325.
2. + T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-941.
3. Pape GR, Gerlach TJ, Diepolder HM, Gruener N, Jung MC, Santantonio T. Role of the specific T cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999;6:36-40.
4. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 2000;30:2479-2487.
5. + T lymphocytes after infection with hepatitis C virus. J Virol 2001;75:5550-5558.
6. Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G, Matz B, Kaiser R, Sauerbruch T, Spengler U. T and B cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996;24:790-795.
7. Derres K, Schild H, Wiesmüller K-H, Jung G, Rammensee H-G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989;42:561-564.
8. Loing E, Andrieu M, Thiam K, Schorner D, Wiesmuller KH, Hosmalin A, Jung G, Gras-Masse H. Extension of HLA-A*0201-restricted minimal epitope by N-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells. J Immunol 2000;164, 900-907.
9. Loing E, Delanoye A, Sergheraert C, Tartar A, Gras-Masse H. Assessing delivery of lipopeptides into the cytoplasm of intact cells by a functional assay based on PKC inhibition. I. The Jurkat model. Pept Res 1996;9, 229-232.
10. Andrieu M, Desoutter JF, Loing E, Gaston J, Hanau D, Guillet JG, Hosmalin A. Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol 2003;77:1564-1570.
11. Düesberg U, Bussche vd A, Kirschning CJ, Miyake K, Sauerbruch T, Spengler U. Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV) -core protein is mediated by tolllike receptors (TLRs) 2 and 4. Immunol Lett 2002;89:89-95.
12. Sieling PA, Chung W, Duong BT, Godowski PJ, Modlin RL. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J Immunol 2003;170:194-200.
13. Langhans B, Braunschweiger I, Schweitzer S, Jung G, Inchauspe G, Sauerbruch T, Spengler U. Lipidation of T helper sequences from hepatitis C virus core significantly enhance T-cell activity in vitro. Immunology 2001;102:460-465.
14. Langhans B, Schweitzer S, Nischalke HD, Braunschweiger I, Sauerbruch T, Spengler U. Hepatitis C virus (HCV)-derived lipopeptides differentially induce epitope-specific immune responses in vitro. J Infect Dis 2004;189:248-253.
15. Langhans B, Braunschweiger I, Schweitzer S, Sauerbruch T, Spengler U. Primary immunisation of Hepatitis C virus (HCV)-specific antibody producing B cells by lipidated peptides. Vaccine 2004;22:1441-1447.
16. Schweitzer S, Schneiders AM, Langhans B, Kraas W, Jung G, Vidalin O, Inchauspé G, Sauerbruch T, Spengler U. Flow cytometric analysis of peptide binding to major histocompatibility complex class 1 for hepatitis C virus core T-cell epitopes. Cytometry 2000;41:271-278.
17. Langhans B, Lechmann M, Ihlenfeldt H, Jung G, Giers G, Schweitzer S, El Bakri M, Sauerbruch T, Spengler U. A hepatitis C virus (HCV) core protein-derived peptide inhibits HCV-specific lymphocyte proliferation. Eur J Med Res 2000;5:115-120.
18. + T cells in chronic hepatitis C virus infection. J Immunol 2002;169:34447-34458.
19. Flieger D, Gruber R, Schlimok G, Reiter C, Pantel K, Riethmüller G. A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. J Immunol Methods 1995;180:1-13.
20. Düesberg U, Schneiders AM, Flieger D, Inchauspé G, Sauerbruch T, Spengler U. Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J Hepatol 2001;35:650-657.
21. Ahrendt M. Evaluierung und Optimierung zytotoxischer Assays zur Detektion von Zytotoxizität bei nur geringer Anzahl von Effektorzellen [diploma thesis]. Oldenburg, Germany: Carl von Ossietzky Universität Oldenburg; 2004.
22. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235-246.
23. Liu L, Chahroudi A, Silvestri G, Wernett ME, Kaiser WJ, Safrit JT, Komoriya A, Altman JD, Packard BZ, Feinberg MB. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorochromic caspase substrates. Nat Med 2002;8:185-189.
24. Isaaz S, Baetz K, Olsen K, Podack E, Griffith GM. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol 1995;25:1071-1079.
25. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;0:621-667.
26. Langhans B, Braunschweiger I, Sauerbruch T, Spengler U. Induction of epitope-specific immune responses by hepatitis C virus (HCV)-derived lipopeptides using monocytes versus monocyte-derived dendritic cells. J Hepatol 2004;403(suppl 1):120:242A.
27. Nattermann J, Nischalke HD, Hofmeister V, Ahlenstiel G, Weiss EH, Sauerbruch T, Spengler U. The HLA-A2 restricted T cell epitope HCV core35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol 2005;166:443-453.
28. Nattermann J, Nischalke HD, Hofmeister V, Kupfer B, Feldmann G, Ahlenstiel G, Weiss EH, Sauerbruch T, Spengler U. Infection with HIV-1 results in increased expression of HLA-E resulting in impaired cytotoxic function of natural killer cells. Antivir Ther 2005;10:95-107.
29. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998;188:2205-2213.
30. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med 1999;5:677-685.
31. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000;192:63-75.
32. Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastoenterology 2001;121:1158-1166.
33. Spencer JV, Braciale TJ. Incomplete CD8+ T lymphocyte differentiation as a mechanism for subdominant cytotoxic T lymphocyte responses to a viral antigen. J Exp Med 2000;10:1687-1698.
34. Cao W, Tykodi SS, Esser MT, Braciale VL, Braciale TJ. Partial activation of CD8+ T cells by self-derived peptides. Nature 1995;378:295-298.
35. Kessler B, Hudrisier D, Schroeter M, Tschopp J, Cerottini JC, Luescher IF. Peptide modification of blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production. J Immunol 1998;161:6939-6946.
36. Fuller CL, Braciale VL. Selective induction of CD8+ cytotoxic T lymphocyte effector function by staphylococcus enterotoxin B. J Immunol 1998;161:5179-5186.
37. Tau GZ, Cowan SN, Weisburg J, Braunstein NS, Rothman PB. Regulation of IFN-gamma signalling is essential for the cytotoxic activity of CD8+ T cells. J Immunol 2001;167:5574-5582.
38. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002;20:323-370.
39. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002;99:15661-15668.